

(80136)

Medical Benefit		Effective Date: 01/01/15	Next Review Date: 09/18
Preauthorization	Yes	Review Dates: 05/09, 03/10, 09/10, 03/11, 03/12, 03/13, 03/14, 09/14, 09/15, 09/16, 09/17	

Preauthorization is required.

The following protocol contains medical necessity criteria that apply for this service. The criteria are also applicable to services provided in the local Medicare Advantage operating area for those members, unless separate Medicare Advantage criteria are indicated. If the criteria are not met, reimbursement will be denied and the patient cannot be billed. Please note that payment for covered services is subject to eligibility and the limitations noted in the patient’s contract at the time the services are rendered.

Description

Extracorporeal photopheresis (ECP) is a leukapheresis-based immunomodulatory procedure that involves the following steps:

1. Patient blood is collected into a centrifuge system that separates the leukocyte-rich portion (buffy coat) from the rest of the blood.
2. The photosensitizer agent 8-methoxypsoralen (8-MOP) is added to the lymphocyte fraction, which is then exposed to ultraviolet (UV) A (320-400 nm wavelength) light at a dose of 1-2 J/cm².
3. The light-sensitized lymphocytes are reinfused into the patient.

ECP has been investigated for the treatment of patients with a variety of autoimmune diseases, graft-versus-host disease (GVHD), T-cell lymphoma (TCL), treatment for and prevention of organ rejection after solid organ transplant, and other miscellaneous conditions.

Summary of Evidence

Organ Rejection After Solid Organ Transplant

Heart

Evidence for the use of ECP in cardiac transplant recipients relates to three indications: acute rejection; recurrent, multiple and/or refractory rejection; and prevention of rejection. For acute rejection and for prevention of rejection, two small randomized trials provide insufficient evidence to permit conclusions concerning the effect of ECP on net health outcome. Therefore, ECP is considered investigational for the treatment and prevention of acute rejection in cardiac transplant recipients. Studies with more patients and longer follow-up are needed. For recurrent, multiple and/or refractory cardiac allograft rejection, evidence to date provides consistent evidence for a beneficial effect of ECP for cardiac transplant patients with rejection refractory to standard therapy. Therefore, ECP is considered medically necessary for the treatment of recurrent, multiple and/or refractory cardiac rejection.

Lung

Evidence for the use of ECP in lung transplant recipients relates to two indications: acute rejection and chronic

rejection refractory to corticosteroids/refractory bronchiolitis obliterans syndrome (BOS). For acute rejection, data are very limited and do not permit any conclusions. This area needs a prospective, randomized, clinical trial focused specifically on the treatment of patients with acute rejection. For treatment of refractory BOS, data are nonrandomized and uncontrolled and show inconsistent results across BOS grades. Prospective, randomized controlled trials (RCTs) are necessary with analyses stratified by BOS grade. Therefore, ECP is considered investigational when used in lung transplantation.

Liver

In liver transplantation, evidence to date has focused on prevention of rejection with ECP. This evidence is insufficient to permit conclusions concerning the effect of ECP on net health outcome. There is a need for RCTs comparing immunosuppressive therapy alone to immunosuppressive therapy with ECP. Therefore, ECP is considered investigational in liver transplant patients for any indication.

Kidney

For renal transplant recipients, evidence comprises small case series in patients with refractory rejection. This evidence is insufficient to permit conclusions concerning the effect of ECP on net health outcome. RCTs comparing immunosuppressive therapy with immunosuppressive therapy with ECP and examining histologic confirmation of treatment response are needed. Therefore, ECP is considered investigational in renal transplant patients for any indication.

Graft-Versus-Host Disease

Evidence for the use of ECP for the treatment of GVHD relates to both acute GVHD (aGVHD) and chronic (cGVHD) in pediatric and adult populations. Evidence comprises retrospective reviews and nonrandomized comparisons and consistently shows improvement in GVHD that is unresponsive to standard therapy. Additionally, there is a lack of other treatment options for these patients; adverse effects of ECP are minimal; and, if there is a response to ECP, patients may be able to reduce or discontinue treatment with corticosteroids and other immunosuppressive agents. Clinical input unanimously supported the use of ECP in patients with refractory aGVHD. Therefore, treatment of refractory aGVHD or cGVHD with ECP is considered medically necessary.

For patients with untreated disease or those who are showing improvement on standard therapy, there is no data to support the use of ECP. Therefore, ECP is considered investigational in these settings.

Autoimmune Disease

Evidence for the use of ECP for the treatment of autoimmune diseases including multiple sclerosis and cutaneous or visceral manifestations of autoimmune diseases, including but not limited to scleroderma, systemic lupus erythematosus, rheumatoid arthritis, pemphigus, psoriasis, autoimmune bullous disorders, severe atopic dermatitis, Crohn disease, and diabetes, is sparse and insufficient to permit conclusions. Therefore, treatment of autoimmune diseases with ECP is considered investigational.

T-Cell Lymphoma

Cutaneous T-Cell Lymphoma

Evidence from small case series has shown a response to ECP in patients with advanced stage cutaneous T-cell lymphoma (CTCL), as well as prolongation of survival in a proportion of patients. Therefore, ECP may be considered medically necessary as a technique for the treatment of patients with stages III/IV CTCL.

Given the unfavorable prognosis for patients with early stage CTCL that progresses on nonsystemic therapies, the relative lack of adverse events with ECP compared with other systemic treatments, and the good response rates often observed with ECP, ECP may be considered medically necessary as a technique for the treatment of patients with refractory or progressive early stage CTCL.

In contrast, when early stage CTCL does respond to less-invasive, topical therapies, patients whose disease remains quiescent under such treatments usually experience near-normal life expectancy. As a consequence, ECP is considered investigational as a technique for the treatment of patients with stage I/II CTCL that is either previously untreated or is responding to established therapies.

Non-CTCL/Leukemia

Data from one small case series showed at least a partial response to extracorporeal photopheresis in some patients with refractory noncutaneous T-cell malignancies. More data from larger studies are needed to determine the role of ECP in the treatment of these diseases.

Policy

Organ Rejection after Solid-Organ Transplant

Extracorporeal photopheresis may be considered **medically necessary** to treat cardiac allograft rejection, including acute rejection, that is either recurrent or that is refractory to standard immunosuppressive drug treatment.

Extracorporeal photopheresis is considered **investigational** in all other situations related to treatment or prevention of rejection in solid-organ transplantation.

Acute GVHD

Extracorporeal photopheresis may be considered **medically necessary** as a technique to treat acute graft-versus-host disease (GVHD) that is refractory to medical therapy.

Extracorporeal photopheresis is considered **investigational** as a technique to treat acute GVHD that is either previously untreated or is responding to established therapies.

Chronic GVHD

Extracorporeal photopheresis may be considered **medically necessary** as a technique to treat chronic GVHD that is refractory to medical therapy.

Extracorporeal photopheresis is considered **investigational** as a technique to treat chronic GVHD that is either previously untreated or is responding to established therapies.

Autoimmune Diseases

Extracorporeal photopheresis is considered **investigational** as a technique to treat either the cutaneous or visceral manifestations of autoimmune diseases, including but not limited to scleroderma, systemic lupus erythematosus, rheumatoid arthritis, pemphigus, psoriasis, multiple sclerosis, diabetes, autoimmune bullous disorders, severe atopic dermatitis, or Crohn disease.

Cutaneous T-cell Lymphoma

Extracorporeal photopheresis may be considered **medically necessary** as a technique to treat late-stage (III/IV) cutaneous T-cell lymphoma.

Extracorporeal photopheresis may be considered **medically necessary** as a technique to treat early stage (I/II) cutaneous T-cell lymphoma that is progressive and refractory to established nonsystemic therapies.

Extracorporeal photopheresis is considered **investigational** as a technique to treat early stage (I/II) cutaneous T-cell lymphoma that is either previously untreated or is responding to established nonsystemic therapies.

Other

Extracorporeal photopheresis is considered **investigational** for all other indications.

Policy Guidelines

Organ Rejection After Solid Organ Transplant

A regimen of immunosuppressive therapy is standard of care for the treatment of solid-organ rejection. Therefore, refractory rejection is defined as rejection that fails to respond adequately to a standard regimen of immunosuppressive therapy.

Recurrent allograft rejection is defined as having at least two rejection episodes that recurred after standard immunosuppressive therapy.

There is no standard schedule for extracorporeal photopheresis, and reported schedules vary by the organ type. However, most reported cardiac and lung schedules initiate therapy with two consecutive days of extracorporeal photopheresis in month one, followed by biweekly therapy on two consecutive days in months two and three, then monthly on two consecutive days in months four through six.

Graft-Versus-Host Disease

Methylprednisolone is considered first-line treatment of acute GVHD. For chronic GVHD, an alternating regimen of cyclosporine and prednisolone is commonly used; other therapies include antithymocyte globulin, corticosteroid monotherapy, and cytotoxic immunosuppressive drugs such as procarbazine, cyclophosphamide, or azathioprine. Therefore, refractory disease is defined as GVHD that fails to respond adequately to a trial of any of these therapies.

Treatment schedule and duration of ECP for GVHD have not been optimally defined. Guidelines and consensus statements generally recommend one cycle (i.e., ECP on two consecutive days) weekly for acute GVHD and every two weeks for chronic GVHD. Treatment duration is based on clinical response; discontinuation is generally recommended for no or minimal response.

Cutaneous T-Cell Lymphoma Staging (based on the TNM classification system)

IA: T1N0M0

IB: T2N0M0

IIA: T1-2N1M1

IIB: T3N0-1M0

III: T4N0-1M0

IVA: T1-4N2-3M0

IVB: T1-4N0-3M1

Sézary Syndrome

According to the World Health Organization-European Organization for research and Treatment of Cancer (WHO-EORTC), Sezary syndrome is defined by the triad of erythroderma, generalized lymphadenopathy, and the presence of neoplastic T-cells (Sezary cells) in skin, lymph nodes, and peripheral blood. The International Society of Cutaneous Lymphomas recommends an absolute Sezary cell count of at least 1,000 cells per cubic mm, in the presence of immunophenotypical abnormalities (CD4/CD8 ratio greater than 10; loss of any or all of the T-cell antigens CD2, CD3, CD4, and CD5, or both), or the demonstration of a T-cell clone in the peripheral blood by molecular or cytogenetic methods.

Medicare Advantage

Extracorporeal photopheresis may be considered **medically necessary** for:

- Palliative treatment of skin manifestations of cutaneous T-cell lymphoma that has not responded to other therapy
- Patients with acute cardiac allograft rejection whose disease is refractory to standard immunosuppressive drug treatment; and
- Patients with chronic graft versus host disease whose disease is refractory to standard immunosuppressive drug treatment.

Use for all other conditions would be **investigational**.

Medicare Advantage Policy Guidelines

Extracorporeal photopheresis for the treatment of bronchiolitis obliterans syndrome (BOS) following lung allograft transplantation may have potential to be a benefit for Medicare Advantage members, but only when extracorporeal photopheresis is performed under coverage with evidence development (CED).

Background

Treatment for and Prevention of Organ Rejection After Solid Organ Transplant

The standard of care for treatment of organ transplant rejection is immunosuppression, with the particular regimen dictated by the organ being transplanted. As organ transplantation success rates have improved, more patients are facing the morbidity and mortality associated with immunosuppressive therapies developed to prevent rejection of the transplanted organ. Immunosuppressive therapies are used to lower the responsiveness of the recipient's immune system, decreasing the chance of rejection. Unfortunately, portions of the immune system responsible for the prevention of viral, fungal, and bacterial infection also are affected. This can, in turn, lead to serious infections, including opportunistic infections.

Although first approved for the treatment of CTCL, ECP has more recently been used as a supplement to conventional therapies in the area of solid organ transplantation.¹ Reports of the successful use of ECP in human cardiac transplant recipients were published in 1992^{2,3} and use in other transplant patients followed. Although the specific mechanism of action of ECP is unknown, the reinfusion of treated leukocytes seems to specifically suppress the patient's immune response to the donor organ, although maintaining the body's ability to respond to other antigens.⁴ The specificity of ECP to target the immune response to the transplanted organ allows ECP to decrease organ rejection without an increased risk of infection, common with immunosuppressive drugs.⁵

Treatment of GVHD

ECP as a treatment of GVHD after a prior allogeneic stem cell transplant is based on the fact that GVHD is an immunologically mediated disease. GVHD can be categorized into acute disease, occurring within the first 100 days after infusion of allogeneic cells, or chronic disease, which develops sometime after 100 days. Acute GVHD is commonly graded from I to IV, ranging from mild disease, which is characterized by a skin rash without involvement of the liver or gut, to grades III and IV, which are characterized by generalized erythroderma, elevated bilirubin levels, or diarrhea. Grade III aGVHD is considered severe, and grade IV is considered life-threatening. Chronic GVHD typically presents with more diverse symptomatology resembling autoimmune diseases such as progressive systemic sclerosis, systemic lupus erythematosus, or rheumatoid arthritis. Chronic GVHD may affect the mouth, eyes, respiratory tract, musculoskeletal system, and peripheral nerves, as well as the skin, liver, or gut—the usual sites of aGVHD.

Treatment of Autoimmune Disease

The use of ECP as a treatment of autoimmune disease is based on the premise that pathogenic lymphocytes form an expanded clone of cells, which are damaged when exposed to UV light in the presence of 8-MOP. It is hypothesized that the resulting damage induces a population of circulating suppressor T cells targeted against the light-damaged cells. It is further hypothesized that these suppressor T cells are targeted at a component of the cell that is common to the entire clone of abnormal cells (i.e., not just the light-sensitized cells), thus inducing a systemic effect. However, although scleroderma and other autoimmune diseases are associated with the presence of circulating autoantibodies, it is unknown how these antibodies are related to the pathogenesis of the disease. As discussed in this policy, photopheresis is not associated with consistent changes in autoantibody levels.

Treatment of T-Cell Lymphoma

Cutaneous T-Cell Lymphoma

According to the National Cancer Institute, CTCL is a neoplasia of malignant T lymphocytes that initially presents as skin involvement. CTCL is extremely rare, with an estimated incidence of approximately 0.4 per 100,000 annually, but because most are low-grade malignancies with long survival, overall prevalence is much higher. Two CTCL variants, mycosis fungoides and the Sézary syndrome, account for approximately 60% and 5% of new cases of CTCL, respectively.

CTCL is included in the Revised European-American Lymphoma classification as a group of low-grade T-cell lymphomas, which should be distinguished from other T-cell lymphomas that involve the skin, such as anaplastic large cell lymphoma, peripheral T-cell lymphoma, adult T-cell leukemia/lymphoma (usually with systemic involvement), or subcutaneous panniculitic T-cell lymphoma. In addition, a number of benign or very indolent conditions can be confused with mycosis fungoides, further complicating diagnosis. See the Policy Guidelines for the current staging classification of CTCL using the tumor, node, metastasis (TNM) classification system.

Mycosis fungoides typically progresses from an eczematous patch/plaque stage, covering less than 10% of the body surface (T1), to a plaque stage, covering 10% or more of the body surface (T2), and finally to tumors (T3) that frequently undergo necrotic ulceration. Sézary syndrome is an advanced form of mycosis fungoides with generalized erythroderma (T4) and peripheral blood involvement (B1) at presentation. Cytologic transformation from a low-grade lymphoma to a high-grade lymphoma sometimes occurs during the course of these diseases and is associated with poor prognosis. A common cause of death during the tumor phase is sepsis from *Pseudomonas aeruginosa* or *Staphylococcus aureus* caused by chronic skin infection with staphylococcus species and subsequent systemic infections.

The natural history of mycosis fungoides is typically indolent. Symptoms may present for long periods (mean, two-10 years) as waxing and waning cutaneous eruptions before biopsy confirmation. The prognosis of patients with mycosis fungoides/Sézary syndrome is based on the extent of disease at presentation and its stage. Lymphadenopathy and involvement of peripheral blood and viscera increase in likelihood with worsening cutaneous involvement and define poor prognostic groups. Median survival after diagnosis varies according to stage. Median survival in patients with stage IA disease exceeds 20 years, with most deaths in this group typically unrelated to mycosis fungoides. In contrast, median survival in patients with stage III through stage IV disease is less than five years; more than 50% of these patients die of their disease.

Appropriate therapy of CTCL depends on a variety of factors, including stage, the patient's overall health, and the presence of symptoms. In general, therapies can be categorized into topical and systemic treatments that include ECP. In contrast to more conventional lymphomas, CTCL, possibly excepting ones in the earliest stages, is not curable. Thus, systemic cytotoxic chemotherapy is avoided except for advanced stage cases. Partial or complete remission is achievable, although most patients require lifelong treatment and monitoring.

Peripheral T-Cell Lymphoma

Peripheral T-cell lymphoma (PTCL) is a group of rare and usually aggressive non-Hodgkin lymphomas that develop from mature T cells. PTCL comprises approximately 10% to 15% of all cases of non-Hodgkin lymphoma in the United States and generally occurs in adults 60 years of age or older. Standards of care are evolving, including the use of hematopoietic stem cell transplantation.⁶

Regulatory Status

FDA has approved via premarket application two photopheresis systems manufactured by Therakos™ Inc. (West Chester, PA). Both systems are approved for use in ultraviolet A (UVA) irradiation treatment, in the presence of the photoactive drug 8-MOP, of extracorporeally circulating leukocyte-enriched blood, in the palliative treatment of skin manifestations of CTCL, in persons who have not been responsive to other forms of treatment. The two systems are:

1. UVAR® XTS Photopheresis System, FDA approved in 1987.
2. CELLEX®, FDA approved in 2009.

8-MOP (UVADEX®) is FDA approved for extracorporeal administration with the UVAR XTS or CELLEX Photopheresis System in the palliative treatment of the skin manifestations of CTCL that is unresponsive to other forms of treatment.

The use of either Therakos Photopheresis System or UVADEX® for other conditions is an off-label use of an FDA-approved device/drug. FDA product code: LNR.

Services that are the subject of a clinical trial do not meet our Technology Assessment Protocol criteria and are considered investigational. *For explanation of experimental and investigational, please refer to the Technology Assessment Protocol.*

It is expected that only appropriate and medically necessary services will be rendered. We reserve the right to conduct prepayment and postpayment reviews to assess the medical appropriateness of the above-referenced procedures. **Some of this protocol may not pertain to the patients you provide care to, as it may relate to products that are not available in your geographic area.**

References

We are not responsible for the continuing viability of web site addresses that may be listed in any references below.

1. Marques MB, Tuncer HH. Photopheresis in solid organ transplant rejection. J Clin Apher. Apr 2006; 21(1):72-77. PMID 16619230
2. Costanzo-Nordin MR, Hubbell EA, O'Sullivan EJ, et al. Photopheresis versus corticosteroids in the therapy of heart transplant rejection. Preliminary clinical report. Circulation. Nov 1992; 86(5 Suppl):II242-250. PMID 1424007
3. Rose EA, Barr ML, Xu H, et al. Photochemotherapy in human heart transplant recipients at high risk for fatal rejection. J Heart Lung Transplant. Jul-Aug 1992; 11(4 Pt 1):746-750. PMID 1498142
4. Hivelin M, Siemionow M, Grimbert P, et al. Extracorporeal photopheresis: from solid organs to face transplantation. Transpl Immunol. Jul 2009; 21(3):117-128. PMID 19409991

5. Szczepiorkowski ZM, Bandarenko N, Kim HC, et al. Guidelines on the use of therapeutic apheresis in clinical practice: evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. *J Clin Apher.* Jun 2007; 22(3):106-175. PMID 17394188
6. The Leukemia & Lymphoma Society. Peripheral T-Cell Lymphoma Facts, 2012. <http://www.lls.org/content/nationalcontent/resourcecenter/freeeducationmaterials/lymphoma/pdf/periph eraltcellly mphomafacts.pdf>. Accessed March 3, 2015.
7. Kirklin JK, Brown RN, Huang ST, et al. Rejection with hemodynamic compromise: objective evidence for efficacy of photopheresis. *J Heart Lung Transplant.* Mar 2006; 25(3):283-288. PMID 16507420
8. Dall'Amico R, Montini G, Murer L, et al. Extracorporeal photochemotherapy after cardiac transplantation: a new therapeutic approach to allograft rejection. *Int J Artif Organs.* Jan 2000; 23(1):49-54. PMID 12118837
9. Maccherini M, Diciolla F, Laghi Pasini F, et al. Photopheresis immunomodulation after heart transplantation. *Transplant Proc.* Feb-Mar 2001; 33(1-2):1591-1594. PMID 11267432
10. Lehrer MS, Ruchelli E, Olthoff KM, et al. Successful reversal of recalcitrant hepatic allograft rejection by photopheresis. *Liver Transpl.* Sep 2000; 6(5):644-647. PMID 10980066
11. Carlo WF, Pearce FB, George JF, et al. Single-center experience with extracorporeal photopheresis in pediatric heart transplantation. *J Heart Lung Transplant.* Jun 2014; 33(6):624-628. PMID 24661684
12. Barr ML, Meiser BM, Eisen HJ, et al. Photopheresis for the prevention of rejection in cardiac transplantation. Photopheresis Transplantation Study Group. *N Engl J Med.* Dec 10 1998; 339(24):1744-1751. PMID 9845709
13. Villanueva J, Bhorade SM, Robinson JA, et al. Extracorporeal photopheresis for the treatment of lung allograft rejection. *Ann Transplant.* 2000; 5(3):44-47. PMID 11233043
14. Salerno CT, Park SJ, Kreykes NS, et al. Adjuvant treatment of refractory lung transplant rejection with extracorporeal photopheresis. *J Thorac Cardiovasc Surg.* Jun 1999; 117(6):1063-1069. PMID 10343253
15. Benden C, Speich R, Hofbauer GF, et al. Extracorporeal photopheresis after lung transplantation: a 10-year single-center experience. *Transplantation.* Dec 15 2008; 86(11):1625-1627. PMID 19077900
16. Greer M, Dierich M, De Wall C, et al. Phenotyping established chronic lung allograft dysfunction predicts extracorporeal photopheresis response in lung transplant patients. *Am J Transplant.* Apr 2013; 13(4):911-918. PMID 23406373
17. Jaksch P, Scheed A, Keplinger M, et al. A prospective interventional study on the use of extracorporeal photopheresis in patients with bronchiolitis obliterans syndrome after lung transplantation. *J Heart Lung Transplant.* Sep 2012; 31(9):950-957. PMID 22884382
18. Lucid CE, Savani BN, Engelhardt BG, et al. Extracorporeal photopheresis in patients with refractory bronchiolitis obliterans developing after allo-SCT. *Bone Marrow Transplant.* Mar 2011; 46(3):426-429. PMID 20581885
19. Morrell MR, Despotis GJ, Lublin DM, et al. The efficacy of photopheresis for bronchiolitis obliterans syndrome after lung transplantation. *J Heart Lung Transplant.* Apr 2010; 29(4):424-431. PMID 19853479
20. O'Hagan AR, Stillwell PC, Arroliga A, et al. Photopheresis in the treatment of refractory bronchiolitis obliterans complicating lung transplantation. *Chest.* May 1999; 115(5):1459-1462. PMID 10334173
21. Urbani L, Mazzoni A, Catalano G, et al. The use of extracorporeal photopheresis for allograft rejection in liver transplant recipients. *Transplant Proc.* Dec 2004; 36(10):3068-3070. PMID 15686696
22. Urbani L, Mazzoni A, Colombatto P, et al. Potential applications of extracorporeal photopheresis in liver transplantation. *Transplant Proc.* May 2008; 40(4):1175-1178. PMID 18555142
23. Urbani L, Mazzoni A, De Simone P, et al. Avoiding calcineurin inhibitors in the early post-operative course in high-risk liver transplant recipients: The role of extracorporeal photopheresis. *J Clin Apher.* 2007; 22(4):187-194. PMID 17294458
24. Jardine MJ, Bhandari S, Wyburn KR, et al. Photopheresis therapy for problematic renal allograft rejection. *J Clin Apher.* 2009; 24(4):161-169. PMID 19536814
25. Kumlien G, Genberg H, Shanwell A, et al. Photopheresis for the treatment of refractory renal graft rejection. *Transplantation.* Jan 15 2005; 79(1):123-125. PMID 15714180

26. Dall'Amico R, Murer L. Extracorporeal photochemotherapy: a new therapeutic approach for allograft rejection. *Transfus Apher Sci*. Jun 2002; 26(3):197-204. PMID 12126206
27. Dall'Amico R, Murer L, Montini G, et al. Successful treatment of recurrent rejection in renal transplant patients with photopheresis. *J Am Soc Nephrol*. Jan 1998; 9(1):121-127. PMID 9440096
28. Baron ED, Heeger PS, Hricik DE, et al. Immunomodulatory effect of extracorporeal photopheresis after successful treatment of resistant renal allograft rejection. *Photodermatol Photoimmunol Photomed*. Apr 2001; 17(2):79-82. PMID 11338406
29. Sunder-Plassman G, Druml W, Steininger R, et al. Renal allograft rejection controlled by photopheresis. *Lancet*. Aug 19 1995; 346(8973):506. PMID 7637500
30. Center for Medicare and Medicaid Services (CMS). National Coverage Determination (NCD) for Extracorporeal Photopheresis (110.4). <http://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=113&ncdver=3&bc=AAAAGAAAAAAA%3d%3d&>. Accessed March 3, 2015.
31. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Extracorporeal photopheresis for graft-versus-host disease. TEC Assessments 2001; Volume 16, Tab 9.
32. Perotti C, Del Fante C, Tinelli C, et al. Extracorporeal photochemotherapy in graft-versus-host disease: a longitudinal study on factors influencing the response and survival in pediatric patients. *Transfusion*. Jun 2010; 50(6):1359-1369. PMID 20113452
33. Halle P, Paillard C, D'Incan M, et al. Successful extracorporeal photochemotherapy for chronic graft-versus-host disease in pediatric patients. *J Hematother Stem Cell Res*. Jun 2002; 11(3):501-512. PMID 12183835
34. Salvaneschi L, Perotti C, Zecca M, et al. Extracorporeal photochemotherapy for treatment of acute and chronic GVHD in childhood. *Transfusion*. Oct 2001; 41(10):1299-1305. PMID 11606832
35. Berger M, Pessolano R, Albiani R, et al. Extracorporeal photopheresis for steroid resistant graft versus host disease in pediatric patients: a pilot single institution report. *J Pediatr Hematol Oncol*. Oct 2007; 29(10):678-687. PMID 17921848
36. Weitz M, Strahm B, Meerpohl JJ, et al. Extracorporeal photopheresis versus standard treatment for acute graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients. *Cochrane Database Syst Rev*. 2014; 2:CD009759. PMID 24569960
37. Weitz M, Strahm B, Meerpohl JJ, et al. Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients. *Cochrane Database Syst Rev*. 2014; 2:CD009898. PMID 24569961
38. OHTAC Recommendation: Extracorporeal Photopheresis. March 28, 2006. http://www.health.gov.on.ca/english/providers/program/ohtac/tech/recommend/rec_ecp_032806.pdf. Accessed March 3, 2015.
39. Malik MI, Litzow M, Hogan W, et al. Extracorporeal photopheresis for chronic graft-versus-host disease: a systematic review and meta-analysis. *Blood Res*. Jun 2014; 49(2):100-106. PMID 25025011
40. Flowers ME, Apperley JF, van Besien K, et al. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. *Blood*. Oct 1 2008; 112(7):2667-2674. PMID 18621929
41. Foss FM, DiVenuti GM, Chin K, et al. Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors. *Bone Marrow Transplant*. Jun 2005; 35(12):1187-1193. PMID 15852025
42. Dignan FL, Aguilar S, Scarisbrick JJ, et al. Impact of extracorporeal photopheresis on skin scores and quality of life in patients with steroid-refractory chronic GVHD. *Bone Marrow Transplant*. Feb 24 2014. PMID 24566709
43. Zhang H, Chen R, Cheng J, et al. Systematic review and meta-analysis of prospective studies for ECP treatment in patients with steroid-refractory acute GVHD. *Patient Prefer Adherence*. 2015; 9:105-111. PMID 25653504

44. Greinix HT, Knobler RM, Worel N, et al. The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. *Haematologica*. Mar 2006; 91(3):405-408. PMID 16531267
45. Perfetti P, Carlier P, Strada P, et al. Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD. *Bone Marrow Transplant*. Nov 2008; 42(9):609-617. PMID 18660840
46. Shaughnessy PJ, Bolwell BJ, van Besien K, et al. Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant*. Jun 2010; 45(6):1068-1076. PMID 19915634
47. Jagasia M, Greinix H, Robin M, et al. Extracorporeal photopheresis versus anticytokine therapy as a second-line treatment for steroid-refractory acute GVHD: a multicenter comparative analysis. *Biol Blood Marrow Transplant*. Jul 2013; 19(7):1129-1133. PMID 23623892
48. Rubegni P, Feci L, Poggiali S, et al. Extracorporeal photopheresis: a useful therapy for patients with steroid-refractory acute graft-versus-host disease but not for the prevention of the chronic form. *Br J Dermatol*. Aug 2013; 169(2):450-457. PMID 23534380
49. Abu-Dalle I, Reljic T, Nishihori T, et al. Extracorporeal photopheresis in steroid-refractory acute or chronic graft-versus-host disease: results of a systematic review of prospective studies. *Biol Blood Marrow Transplant*. Nov 2014; 20(11):1677-1686. PMID 24867779
50. Hautmann AH, Wolff D, Hahn J, et al. Extracorporeal photopheresis in 62 patients with acute and chronic GVHD: results of treatment with the COBE Spectra System. *Bone Marrow Transplant*. Mar 2013; 48(3):439-445. PMID 22922407
51. Ussowicz M, Musial J, Mielcarek M, et al. Steroid-sparing effect of extracorporeal photopheresis in the therapy of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. *Transplant Proc*. Nov 2013; 45(9):3375-3380. PMID 24182819
52. Greinix HT, Volc-Platzer B, Knobler R. Criteria for assessing chronic GVHD. *Bone Marrow Transplant*. Mar 2000; 25(5):575. PMID 10713639
53. Rubegni P, Cuccia A, Sbano P, et al. Role of extracorporeal photochemotherapy in patients with refractory chronic graft-versus-host disease. *Br J Haematol*. Jul 2005; 130(2):271-275. PMID 16029456
54. Das-Gupta E, Dignan F, Shaw B, et al. Extracorporeal photopheresis for treatment of adults and children with acute GVHD: UK consensus statement and review of published literature. *Bone Marrow Transplant*. Oct 2014; 49(10):1251-1258. PMID 24887389
55. Martin PJ, Rizzo JD, Wingard JR, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. Aug 2012; 18(8):1150-1163. PMID 22510384
56. Messina C, Locatelli F, Lanino E, et al. Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation. *Br J Haematol*. Jul 2003; 122(1):118-127. PMID 12823353
57. Dignan FL, Clark A, Amrolia P, et al. Diagnosis and management of acute graft-versus-host disease. *Br J Haematol*. Jul 2012; 158(1):30-45. PMID 22533831
58. Dignan FL, Amrolia P, Clark A, et al. Diagnosis and management of chronic graft-versus-host disease. *Br J Haematol*. Jul 2012; 158(1):46-61. PMID 22533811
59. Scarisbrick JJ, Taylor P, Holtick U, et al. U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease. *Br J Dermatol*. Apr 2008; 158(4):659-678. PMID 18241274
60. Das-Gupta E, Watson L, Byrne J et al. Physicians Poster Sessions. P503: a single-centre experience of the efficacy of extracorporeal photopheresis in the treatment of steroid-refractory acute graft-versus-host disease. *Bone Marrow Transplant* 2011; 46(S1):S114.
<http://www.nature.com/bmt/journal/v46/n1s/index.html>. Accessed March 3, 2015.

61. Pierelli L, Perseghin P, Marchetti M, et al. Extracorporeal photopheresis for the treatment of acute and chronic graft-versus-host disease in adults and children: best practice recommendations from an Italian Society of Hemapheresis and Cell Manipulation (SIdEM) and Italian Group for Bone Marrow Transplantation (GITMO) consensus process. *Transfusion*. Oct 2013; 53(10):2340-2352. PMID 23305044
62. National Cancer Institute. Childhood Hematopoietic Cell Transplantation (PDQ®), last modified 04/08/14. http://www.cancer.gov/cancertopics/pdq/treatment/childHCT/HealthProfessional/page1/AllPages#Section_59. Accessed March 3, 2015.
63. Bredeson C, Rumble RB, Varela NP, et al. Extracorporeal photopheresis in the management of graft-versus-host disease. *Curr Oncol*. Apr 2014; 21(2):e310-325. PMID 24764713
64. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Extracorporeal photopheresis for autoimmune disease. *TEC Assessments 2001; Volume 16, Tab 10*.
65. Rook AH, Freundlich B, Jegasothy BV, et al. Treatment of systemic sclerosis with extracorporeal photochemotherapy. Results of a multicenter trial. *Arch Dermatol*. Mar 1992; 128(3):337-346. PMID 1550365
66. Fries JF, Seibold JR, Medsger TA, Jr. Photopheresis for scleroderma? No! *J Rheumatol*. Jul 1992; 19(7):1011-1013. PMID 1512753
67. Melski JW. Price of technology. A blind spot. *JAMA*. Mar 18 1992; 267(11):1516-1518. PMID 1538542
68. Trentham DE. Photochemotherapy in systemic sclerosis. The stage is set. *Arch Dermatol*. Mar 1992; 128(3):389-390. PMID 1550373
69. Ludvigsson J, Samuelsson U, Ernerudh J, et al. Photopheresis at onset of type 1 diabetes: a randomised, double blind, placebo controlled trial. *Arch Dis Child*. Aug 2001; 85(2):149-154. PMID 11466190
70. Cavaletti G, Perseghin P, Dassi M, et al. Extracorporeal photochemotherapy: a safety and tolerability pilot study with preliminary efficacy results in refractory relapsing-remitting multiple sclerosis. *Neurol Sci*. Apr 2006; 27(1):24-32. PMID 16688596
71. Sanli H, Akay BN, Ayyildiz E, et al. Remission of severe autoimmune bullous disorders induced by long-term extracorporeal photochemotherapy. *Transfus Apher Sci*. Dec 2010; 43(3):353-359. PMID 21035398
72. Papp G, Horvath IF, Barath S, et al. Immunomodulatory effects of extracorporeal photochemotherapy in systemic sclerosis. *Clin Immunol*. Feb 2012; 142(2):150-159. PMID 22036269
73. Rubegni P, Poggiali S, Cevenini G, et al. Long term follow-up results on severe recalcitrant atopic dermatitis treated with extracorporeal photochemotherapy. *J Eur Acad Dermatol Venereol*. Apr 2013; 27(4):523-526. PMID 22540319
74. Wolf P, Georgas D, Tomi NS, et al. Extracorporeal photochemotherapy as systemic monotherapy of severe, refractory atopic dermatitis: results from a prospective trial. *Photochem Photobiol Sci*. Jan 2013; 12(1):174-181. PMID 22948099
75. Reinisch W, Knobler R, Rutgeerts PJ, et al. Extracorporeal photopheresis (ECP) in patients with steroid-dependent Crohn's disease: an open-label, multicenter, prospective trial. *Inflamm Bowel Dis*. Feb 2013; 19(2):293-300. PMID 22573600
76. Knobler R, Berlin G, Calzavara-Pinton P, et al. Guidelines on the use of extracorporeal photopheresis. *J Eur Acad Dermatol Venereol*. Jan 2014; 28 Suppl 1:1-37. PMID 24354653
77. Edelson R, Berger C, Gasparro F, et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. *N Engl J Med*. Feb 5 1987; 316(6):297-303. PMID 3543674
78. Knobler R, Duvic M, Querfeld C, et al. Long-term follow-up and survival of cutaneous T-cell lymphoma patients treated with extracorporeal photopheresis. *Photodermatol Photoimmunol Photomed*. Oct 2012; 28(5):250-257. PMID 22971190
79. Freiman A, Sasseville D. Treatment of mycosis fungoides: overview. *J Cutan Med Surg*. Sep-Oct 2006; 10(5):228-233. PMID 17234106
80. Keehn CA, Belongie IP, Shistik G, et al. The diagnosis, staging, and treatment options for mycosis fungoides. *Cancer Control*. Apr 2007; 14(2):102-111. PMID 17387295
81. Knobler E. Current management strategies for cutaneous T-cell lymphoma. *Clin Dermatol*. May-Jun 2004; 22(3):197-208. PMID 15262305

82. Scarisbrick JJ. Staging and management of cutaneous T-cell lymphoma. *Clin Exp Dermatol*. Mar 2006; 31(2):181-186. PMID 16487086
83. Whittaker SJ, Foss FM. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma. *Cancer Treat Rev*. Apr 2007; 33(2):146-160. PMID 17275192
84. Trautinger F, Knobler R, Willemze R, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome. *Eur J Cancer*. May 2006; 42(8):1014-1030. PMID 16574401
85. Whittaker SJ, Marsden JR, Spittle M, et al. Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. *Br J Dermatol*. Dec 2003; 149(6):1095-1107. PMID 14696593
86. National Cancer Institute. Mycosis Fungoides and the Sézary Syndrome Treatment (PDQ®), updated February 25, 2015. <http://www.cancer.gov/cancertopics/pdq/treatment/mycosisfungoides/HealthProfessional>. Accessed March 3, 2015.
87. Miller JD, Kirkland EB, Domingo DS, et al. Review of extracorporeal photopheresis in early-stage (IA, IB, and IIA) cutaneous T-cell lymphoma. *Photodermatol Photoimmunol Photomed*. Oct 2007; 23(5):163-171. PMID 17803594
88. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. *Blood*. May 15, 2005; 105(10):3768-3785. PMID 15692063
89. Garban F, Carras S, Drillat P, et al. Extracorporeal photopheresis as a curative treatment strategy in non epidermotropic T-cell lymphoma and large granular lymphocyte leukemia. *Ann Oncol*. Sep 2012; 23(9):2386-2390. PMID 22422944
90. Marks DI, Rockman SP, Oziemski MA, et al. Mechanisms of lymphocytotoxicity induced by extracorporeal photochemotherapy for cutaneous T cell lymphoma. *J Clin Invest*. Dec 1990; 86(6):2080-2085. PMID 2123891
91. Jacob MC, Manches O, Drillat P, et al. Quality control for the validation of extracorporeal photopheresis process using the Vilbert-Lourmat UV-A irradiation's system. *Transfus Apher Sci*. Feb 2003; 28(1):63-70. PMID 12620270
92. National Comprehensive Cancer Network (NCCN). Clinical practice guidelines on oncology: non-Hodgkin's lymphomas, v. 2.2015 (discussion update in progress). http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf. Accessed March 3, 2015.
93. National Coverage Determination (NCD) for Extracorporeal Photopheresis (110.4), Effective Date of this Version 4/30/2012.